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Abstract— Cancer complexity and resistance is mediated by 
cell-to-cell heterogeneity, which is the consequence of the 
enormous instability of its genetic material. It is unknown how 
cancer cells are able to withstand the effects of these 
alterations, while normal cells are typically very sensitive. We 
hypothesize that cancer requires specific type of stability to 
survive the enormous chromosomal alterations. This stability 
may be mediated by a group of genes, whose expression is 
tightly regulated to maintain viability through a process called 
gene dosage compensation. This mechanism could be 
mediated by systems-level properties of complex networks of 
microRNAs (miRNA) and transcription factors (TF), 
regulating gene expression despite changes in copy number. 
Therefore, we designed a biocomputational platform to 
automatically construct large-scale mathematical models 
regulating the expression of several candidate genes under 
dosage compensation. This platform has a broader potential 
application to other scientific questions involving miRNA and 
TF networks. 
Keywords—miRNAs, gene dosage compensation, cancer, 
systems biology 
I. Introduction  
Cancer robustness is enabled at the tumor cell population level 
by heterogeneity in therapy responses, which is driven by 
genomic instability[1] , specially by aneuploidy: gains and 
losses of whole or partial chromosomes. It is unknown how 
cancer cells deal with so much aneuploidy whereas normal 
cells are very sensitive. A possible explanation is given by the 
hypothesis of gene dosage compensation, a mechanism that 
has been described for other organisms to compensate the 
negative effects of aneuploidy [2]. It has been shown for 
aneuploid cancers that messenger RNA (mRNA) levels 
generally correlate well with an increased DNA copy number 
(gene dosage) but these changes are not reflected at the protein 
levels for several genes [3]. Several lines of evidence suggest 
the existence of a gene dosage compensation mechanism that 
provides stability to cancer despite its genomic instability. 
However, this mechanism must be able to regulate the 
expression of a handful of critical genes simultaneously. We 
hypothesize the existence of a complex regulatory network 
mediated by microRNAs (miRNAs) to compensate for gene 
dosage changes in aneuploid cancer cells. miRNAs are small 
endogenous RNA molecules that bind mRNAs and repress 
gene expression [4]. Currently, 1500 miRNAs have been 
described within the human genome [5] regulating the 
expression of nearly 30% of all genes [6]. Additionally, 
miRNAs can regulate hundreds of genes and their target genes 
can be regulated by several miRNAs [7]. Furthermore, they 
form regulatory interactions with transcription factors 
including feedback and feedforward loops leading to non-
linear, systems-level properties such as bistability, 
ultrasensitivity and oscillations [8]. We suggest that the 
manipulation of specific nodes of this miRNA-based 
regulatory network could block gene dosage compensation, 
representing a specific target against cancer. Due to the 
complexity of this network, identification of optimal targets 
requires an advanced computational platform. 
II. Materials and Methods 
A. Data sources and biocomputational 
platform 
 
For the biocomputational platform we gathered data from 
several sources. The primary sources were from experiments 
on the NCI60 panel: gene copy number [17], RNA gene 
expression [18] and protein expression [11]. MicroRNA 
related data was downloaded from Mirtarbase [19] and 
MiRBase [20]. For gene regulation data we relied on several 
sources: Transmir [21], Pazar [22], TRED (Transcriptional 
Regulatory Element Database) [23], CircuitsDB [24].  
B. Gene classification using Gaussian 
Mixture Models 
In order to classify genes according to their behavior, we 
developed a computer algorithm based on the Gaussian 
Mixture Model functions in MATLAB. An increasing number 
of components (ki) of the GMM model is added sequentially 
and the GMM training is performed for several iterations 
searching for the best fit to the experimental data. The 
resulting GMM is used to classify the cells of the original data 
set. A MANOVA test is applied to the resulting clusters to 
evaluate statistically the biological significance of adding 
another component to the GMM until the new component adds 
no further significance, finding thereby the optimal number of 
components with biological meaning.  
C. Ordinary differential equation 
modeling of miRNA-TF networks 
From the list of genes selected by the GMM we identified the 
miRNAs an TFs regulating each gene. We build the network 
topology using these three types of species as nodes and the 
regulation relations as edges. In the SBML model we defined 
each node as specie. For each species we defined two 
parameters:  synthesis and degradation rates. For miRNAs we 
also define the repression rate and for TFs we defined 
activation and repression rates. Finally, we added synthesis 
and degradation reactions for each species in the SBML. We 
also created experimental data files using CGH, RNA and 
microRNA expression. We imported the model into COPASI. 
Once in COPASI we included the experimental data files, 
fitted the model with the Parameter Estimation Task. 
 
 
 
 
 
 
Figure 1. Identification of candidate genes under dosage compensation. A. Input data of gene copy number (DNA), gene expression (RNA) and protein levels (protein) of 
the NCI60 panel. The absolute values are shown on the left panel and the right panel corresponds to the log2 values normalized to the averaged RNA and protein of the 
diploid cell lines for the respective gene (Normalized to diploid). B. Gaussian Mixture Model to identify a cluster of subpopulation of genes with high SD DNA and low SD 
RNA and/or low SD Protein (white arrow). C. Gene Clustering according to the model in B showing the standard deviations (SD) of the DNA, RNA and protein levels for 
each gene across the 59 cell lines of the NCI60 panel. The cyan cluster contains candidate genes under dosage compensation, characterized by high SD DNA, low SD 
Protein (middle) and low SD RNA (right). D. Absolute and Normalized values of selected candidate genes under dosage compensation. E. Examples of candidate genes 
under dosage compensation (MYC and RAB5C) compared to a non-candidate gene (SAV1). 
III. Results  
A. Candidate genes under gene dosage 
compensation are present across the 
NCI-60 panel 
In order to identify possible genes under gene dosage 
compensation, we compared copy number, gene expression 
and proteomic data of the NCI60 panel. We considered input 
data including high resolution Copy Number Variation data 
(DNA) of the NCI-60 Cancer Cell lines from 4 different 
platforms [9], the Gene Transcript  (RNA) Average Intensities 
of 5 Platforms [10], and the protein levels (Protein) of a global 
proteome analysis of the NCI-60 cell line panel [11]. Figure 
1A left shows the relative variation of these absolute DNA, 
RNA and Protein levels. However, once we normalized the 
data in the same way (log2 values normalized to the averaged 
RNA and protein of the diploid cell lines for the respective 
gene), it can be observed in Figure 1A right that the DNA 
values have a higher amplitude, followed by RNA levels and 
protein levels. 
Indeed, we are interested in those genes with high variation in 
DNA levels and low variation in RNA or protein levels, as 
candidates to study possible mechanisms of gene dosage 
compensation. Therefore, we considered the Standard 
Deviation (SD) of the DNA, RNA and Protein values across 
the 59 cell lines and classify those genes using a Gaussian 
mixture model (GMM) from the data (Figure 1B). One cluster 
was identified having high SD of DNA values and 
proportionally low SD of RNA and SD of Protein values 
(Figure 1C). The genes contained within this cluster presented 
the behaviour of interest (Figure 1D), where the corresponding 
SD of RNA and/or Protein is proportionally low compared to 
the high SD of DNA values. Moreover, we discarded those 
genes with orthologues in X/Y chromosomes since they 
cannot be differentiated using with microarray techniques. In 
addition, we discarded genes without any reported interactions 
with microRNA or Transcription Factor forming regulatory 
loops (see below). Furthermore, we discarded genes with high 
DNA variation due mostly to deletion (DNA values lower than 
-0.25) and obtained a list of 19 gene candidates under dosage 
compensation including ANKFY1, ATP1B2. PGR, 
DCUN1D5, MMP12, BIRC2, ATM, NPAT, CUL5, STAT3, 
KCNH4, RAB5C, TRIM37, ZNF217 and MTSS1, MYC, 
SEMAD3D, BIRC2, ZNF217, FOXC1 y PDCD10. Among 
those, we can highlight the presence of the oncogene MYC, 
which presents high frequency of amplifications in the NCI60 
panel without the corresponding increase in RNA levels 
(Figure 1E right). For many genes there is also protein data, 
which confirms this behaviour as is the case for RAB5C, 
which RNA and protein levels are maintained quite constant 
despite DNA variations (Figure 1E middle), compared to a 
non-candidate gene such as SAV1 (Figure 1E right).  
These data suggest the existence of 19 candidate genes under 
dosage compensation across the NCI60 panel, partially related 
by common chromosomal locations or other functional 
interactions.  
B. A putative network of miRNA-
transcription factor regulatory loops 
links all candidate genes under 
potential dosage compensation  
miRNAs and transcription factor networks have been 
implicated in regulation of gene expression [12], including 
gene dosage compensation by regulatory feed-forward loops 
[13]. Since there is expression data available of miRNA [14] 
and transcription factors (TF)[10] for the NCI60 panel, we 
asked whether there is a connection between our 19 candidate 
genes and miRNA/transcription factor regulation. In order to 
explore this connection, we calculated the correlation 
coefficients between the Z-scores of copy number variations 
of the candidate genes and the Z-scores of miRNA/TF 
expression data across the NCI60 panel. As depicted in figure 
2A, there are both miRNAs and TF with high positive or 
negative correlation. This result suggests the existence of 
miRNAs and TFs that potentially regulate the expression of 
clusters of candidate genes simultaneously. To evaluate 
whether there are any reported or predicted connections 
between these candidate genes and miRNAs/TF, we 
constructed a network of putative regulatory interactions based 
on the information available at the databases Mirtarbase, 
MiRBase, Pazar, TRED and the study of Neph et al [15]. In 
addition, we included the interactions between miRNAs and 
TFs using the information available at Transmir and 
CircuitsDB 2. This generated a network with 540 nodes and 
 
Figure 2. The workflow starts by analizing CGH and ARN 
variation of the genes. Those genes with high CGH variation and 
low ARN variation are selected. These genes, along with regulation 
relations between transcription factors/microARNs and genes as 
well as to each other are assembled together to conform the 
topology of the gene dosage compensation network. Finally, the 
SBML model of the network is constructed using the list of nodes 
and edges of the network, converting each node into a species and 
using the edges for the reactions of synthesis and degradation in the 
SBML model.  
 
2848 interactions, which connect all 19 candidate genes 
(targets) (Figure 3B). In order to examine the 
target/miRNA/TF network for the presence of regulatory 
interactions with potential activity on gene dosage 
compensation, we searched for motifs with systems-level 
properties including positive and negative feedback loops 
(between miRNAs and TFs), coherent feed-forward loops and 
incoherent feed-forward loops [8]. We identified a total 
number of 2500 putative regulatory motifs. For example, 
miRN15A participates in a coherent feed-forward loop 
inhibiting both SEMAD3 and BRCA1, a positive regulator of 
BRCA1. Also, BRCA1 forms an incoherent feed-forward 
loop, activating the transcription of SEMAD3 but also 
miR195, a negative regulator of SEMAD3. In addition, 
miR15A forms a negative feedback loop with BRCA1 (Figure 
2C). In total, this network includes 78 negative feedback loops 
but no positive feedback loops between TFs and miRNAs, 
1422 coherent feed-forward loops and 1000 incoherent feed-
forward loops formed by the interaction of TFs and miRNAs 
with the target genes. MYC, ZNF217 and STAT3 are the genes 
involved in the majority of regulatory motifs. 
To gain insight into these target/miRNA/TF interactions, we 
calculated the correlation coefficients among the values of the 
elements for each regulatory loop including miRNA levels 
(miR), target copy number (CN) and transcription factor 
 
Figure 3. A putative regulatory network is automatically constructed from available TF and miRNA interaction data. Correlation coefficients of 
candidate target genes with miRNAs and transcription factors (A). Putative network topology of target-miRNA-TF interactions (B) including examples 
of coherent feedforward, incoherent feed-forward and negative feedback loops (C). The correlation coefficients from A are employed to choose those 
forward loops with the highest likelihoods to be real interactions (D). 
expression (TF). The correlations between miR/CN, TF/CN 
and TF/miR displayed a high density around zero for both 
coherent and incoherent feed-forward loops. However, several 
interactions are separated from that central core, suggesting 
that they could participate in real regulatory loops (Figure 2D). 
Therefore, we selected the regulatory loops that could play a 
role in gene dosage compensation, having at least one of its 
correlations separated from the central core. For coherent 
feed-forward loops (where a miRNA inhibits a TF) we 
included loops with a positive miR/CN correlation (higher 
than 0.25), a negative TF/CN correlation (lower than -0.25), or 
a negative miR/TF correlation (lower than -0.25). For the 
incoherent feed-forward loops (where a TF activates a 
miRNA) we selected those with positive miR/CN correlations 
(higher than 0.25), negative CN/TF correlations (lower than -
0.25) or positive TF/miR correlations (higher than 0.35). 
These putative regulatory loops generated a simplified 
regulatory network of the interactions with the highest 
correlations expected for gene dosage compensation (Figure 
3A). 
These results indicate that several putative regulatory loops 
link all the candidate target genes. These regulatory motifs 
with potential systems-level properties are widely present 
within this putative network. The high 
correlation/anticorrelation for the copy number variations of 
some target genes and the expression levels of some 
miRNA/TFs suggests that some of these regulatory motifs 
may be involved in gene dosage compensation. However, the 
assessment of the complexity of this regulatory network 
requires a systems-level approach. 
C. A large scale mathematical model of 
miRNA-transcription factor 
interactions with the candidate genes 
The simplified network includes 434 nodes and 2745 arcs 
(Figure 4A). Due to the high complexity of miRNA/TF 
regulatory netwoks, we proceeded to a systems-level approach 
in order to gain insight into the complexity of the gene dosage 
compensation mediated by miRNAs and TFs. Therefore, we 
constructed a mathematical model using COPASI using our 
automated biocomputational platform considering basic 
network motifs for the target gene, miRNA and TF (Figure 
4B). The biochemical model includes 182 species, 364 
reactions and 823 parameters and was fitted using the 
Parameter Estimation function of COPASI. The resulting 
model presents a good fitting of the data. This result indicates 
that we have now the first large-scale mathematical model to 
perform future studies on gene dosage compensation. 
Taken together, these results indicate that several genes with 
high copy number variations have very low changes in 
expression, suggesting that they are under the influence of 
gene dosage compensation. Those candidate genes are highly 
interconnected with miRNAs and transcription factors leading 
to the formation of different types of regulatory loops that 
could contribute to the mechanism of gene dosage 
compensation. The high complexity of the resulting network 
required a dedicated computational platform for the automatic 
construction of a large-scale mathematical model of gene 
regulation that can be used to perform studies on gene dosage 
compensation. 
IV. Discussion 
We developed a computational platform to automatically 
construct large scale models of miRNAs and TF interactions 
with a novel approach. The classical approach starts with those 
disregulated miRNAs followed by the identification of gene 
targets, which is very inefficient because each miRNA can 
alter the expression of hundreds of genes by only 1.5 to 4 fold 
[8] and it is the cooperative effect of miRNA networks that 
makes them robust regulators [16]. It is therefore very hard to 
identify single miRNA-target interactions with relevant 
biological function, requiring extensive molecular biology 
work for validation. Therefore, we propose the first systems-
level approach in the opposite direction, identifying first 
targets under gene dosage compensation and second, 
identifying their regulating miRNAs. 
To our knowledge, previous bioinformatic work focused on 
miRNA networks based on differential expression data 
between tumoral and normal tissues. Those differences are a 
consequence of genetic instability and as such, highly 
heterogeneous among cancer types, because they arise from 
different evolutionary trajectories of cancer. In contrast, our 
work is the first to explore the core stability of gene 
expression in cancer, which mediates its survival despite its 
genetic instability. This stability core presumably would be 
homogeneous among cells and cancer types; and it might be 
represented by a set of genes tightly regulated by stable 
miRNA networks to ensure gene dosage compensation. 
miRNA networks are robust regulators of gene expression 
upon environmental changes [16] and they show adaptation to 
gene dosage through the formation of regulatory circuits with 
transcription factors [13]. Thus, we hypothesize that cancer 
has a robust Achilles-Heel due to an increased sensitivity to 
perturbations in these circuits, which is not necessarily 
reflected as differences in miRNA expression levels but at 
systems-level properties. 
 In conclusion, the present work led to the construction of a 
complex mathematical model to study gene dosage 
compensation and formulated model-driven hypothesis for the 
identification of novel targets against aneuploid cancer.  
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